Management of Urinary Symptoms in Multiple Sclerosis: An Umbrella Review
Authors:
- Sina HamzehzadehSHSina Hamzehzadeh
- Donyasadat HashemianDHDonyasadat Hashemian
- Saman BaharomidSBSaman Baharomid
- Fateme TahmasebiFTFateme Tahmasebi
- Seyedemad Seyedgholami SharabianiSSSeyedemad Seyedgholami Sharabiani
- Sakineh HajebrahimiSHSakineh Hajebrahimi
- Mahnaz TalebiMTMahnaz Talebi
- Hanieh Salehi‐PourmehrHSHanieh Salehi‐Pourmehr
- Amirreza NaseriANAmirreza Naseri
- 16 October 2026
- journal article
- review article
- Published by Wiley in Neurourology and Urodynamics
Abstract
Background: Lower urinary tract dysfunctions (LUTDs) are prevalent among patients with multiple sclerosis (MS), which is the most common immune‐mediated neurologic disease among the juvenile population. This study aims to evaluate the efficacy and safety of different methods in the management of MS‐related LUTD. Methods: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and Joanna Briggs Institute (JBI) methods. Systematic review studies that reported the efficacy of any management method for LUTD in MS are considered for inclusion. A systematic search was conducted in PubMed, Scopus, Embase, and Web of Science and risk of bias was assessed using the JBI critical appraisal checklist for systematic reviews. Results: Out of 342 screened records, 34 systematic reviews were included. Preliminary efficacy and safety of pelvic floor muscle training (PFMT) and tibial nerve stimulation (TNS), as well as the potential of alpha‐blockers, cannabinoids, mirabegron, spinal cord stimulation, sacral neuromodulation, transcranial neuromodulations, vaginal/rectal and clitoral/penile stimulation, foot reflexology, craniosacral therapy, and stem cell therapy were suggested. Despite the appropriate efficacy, anticholinergics, desmopressin, intradetrusor injections of botulinum toxin A, vanilloids, and catheterization were found to cause considerable side effects. Discussion: Despite a high prevalence of LUTDs in MS patients, evidence basis of the management methods is still poor and there is lack of well‐designed randomized controlled trials, which makes evidence inconclusive. Future research is needed to refine treatment algorithms, investigate the potential of combination therapies, and develop individualized treatment paradigms.Keywords
This publication has 140 references indexed in Scilit:
- Case Report of Acute Severe Hyponatremia Induced by Desmopressin Administration During ChemotherapyClinical Case Reports, 2026
- D-mannose for preventing and treating urinary tract infectionsCochrane Database of Systematic Reviews, 2020
- Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple SclerosisJAMA Network Open, 2018
- Catheterization for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review. A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)Neurourology and Urodynamics, 2018
- Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity—A systematic review and meta‐analysisNeurourology and Urodynamics, 2017
- Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta‐analysis. A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)Neurourology and Urodynamics, 2017
- Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunctionCochrane Database of Systematic Reviews, 2014
- Rituximab for relapsing-remitting multiple sclerosisCochrane Database of Systematic Reviews, 2013
- Management of lower urinary tract dysfunction in multiple sclerosis: A systematic review and Turkish consensus reportNeurourology and Urodynamics, 2013
- Azathioprine for multiple sclerosisCochrane Database of Systematic Reviews, 2007